10-Q: Vystar Corporation Reports First Quarter 2024 Results Amidst Reorganization

Vystar Corporation's Q1 2024 results reflect a significant revenue decrease due to internal reorganization, while also showing a reduced net loss compared to the same period last year.

Summary

• Vystar Corporation reported a revenue of $37,607 for the first quarter of 2024, a significant decrease from $409,907 in the same period of 2023.
• The company's gross profit also decreased substantially to $20,187 from $333,209 year-over-year.
• Operating expenses totaled $357,425, a slight decrease from $383,926 in the first quarter of 2023.
• The net loss from continuing operations was $345,327, compared to a loss of $61,054 in the prior year.
• Discontinued operations resulted in a loss of $29,391, a significant improvement from the $1,216,022 loss in the first quarter of 2023.
• The net loss attributable to Vystar was $362,374, compared to $766,347 in the same period last year.
• The company's cash balance was $11,768 as of March 31, 2024, with a working capital deficit of approximately $6 million.
• Vystar's accumulated deficit stood at approximately $61 million as of March 31, 2024.
• The company has a net operating loss carryforward of approximately $38 million for federal income tax purposes.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, including a substantial revenue decrease, a large working capital deficit, and an accumulated deficit. While there are some positive notes about reorganization and reduced losses from discontinued operations, the overall financial health of the company is concerning.

Positives

• The net loss attributable to Vystar decreased by 52.7% year-over-year.
• The loss from discontinued operations improved significantly, decreasing from $1,216,022 to $29,391.
• The company is focusing on its core product lines, RxAir and Vytex, after a period of reorganization.
• Vystar is working to improve internal reporting systems and procedures.

Negatives

• Vystar experienced a significant decrease in revenue of 90.8% year-over-year.
• Gross profit decreased by 93.9% year-over-year.
• The company has a substantial working capital deficit of approximately $6 million.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has an accumulated deficit of approximately $61 million.

Risks

• The company's ability to continue as a going concern is in doubt due to significant losses and negative cash flow.
• Vystar's future success depends on obtaining sufficient financing and achieving adequate revenue levels.
• The company may need to curtail or reorient operations if it cannot achieve projected revenue or secure additional financing.
• There is no assurance that the company will achieve projected revenue levels in 2024 and beyond.
• The company is subject to legal proceedings and claims that have not been fully resolved.

Future Outlook

The company plans to finance future operations using cash on hand, increased revenue from RxAir air purification units, Vytex license fees, and stock issuances. There is no assurance that the company will achieve projected revenue levels in 2024 and beyond.

Management Comments

• Jamie Rotman took over as CEO to refocus the Company on Vystar's two main product lines, RxAir and Vytex.
• Her focus in the first quarter was additionally to complete the move-out of the Rotmans 250,000 sq ft facility and relocate the inventory.
• Another one of her objectives was to bring the internal reporting systems up to date including procedures to make future reporting and external audits run smoothly.

Industry Context

The company's focus on air purification and natural rubber latex aligns with growing health and sustainability trends. The company is also exploring new applications for its technologies in areas such as water purification and automotive tires.

Comparison to Industry Standards

• The significant revenue decrease of 90.8% year-over-year is a major deviation from industry standards, where companies typically aim for consistent or growing revenue.
• The substantial gross profit decrease of 93.9% year-over-year is also a significant concern, as it indicates a major issue with the company's cost structure or pricing strategy.
• The company's working capital deficit of approximately $6 million is a critical issue, as it suggests the company may struggle to meet its short-term obligations.
• The accumulated deficit of approximately $61 million is also a major concern, as it indicates the company has been consistently losing money over time.
• Compared to other companies in the air purification and natural rubber latex industries, Vystar's financial performance is significantly weaker, suggesting a need for major operational and strategic changes.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in ongoing legal proceedings, including a case with EMA Financial, Inc., which is currently under appeal.

Related Party Transactions

• The company has significant related party transactions with officers, directors, and their affiliated entities, including consulting agreements and advances.
• Jamie Rotman, the current CEO, has an employment agreement with the company.
• Blue Oar Consulting, Inc., owned by the son of the former CEO, provides business consulting services to the company.
• Steven Rotman, the former CEO, has a significant stock subscription payable balance and reimbursable expenses payable.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern issues.
• Employees may be affected by potential operational changes or restructuring.
• Customers may experience disruptions in product availability or service.
• Suppliers and creditors face increased risk of non-payment due to the company's financial challenges.

Next Steps

• The company plans to focus on increasing revenue from RxAir air purifier sales and Vytex license fees.
• The company will continue to explore new applications for its technologies.
• The company will work to improve internal controls and financial reporting processes.

Key Dates

Keywords

Vystar Corporation, RxAir, Vytex, air purification, natural rubber latex, financial results, Q1 2024, reorganization, net loss, revenue, discontinued operations, working capital, going concern